 |
|
Immunologic Competence of Patients With Psoriasis Receiving Cytotoxic Drug Therapy
WILLIAM L. EPSTEIN, MD;
HOWARD I. MAIBACH, MD
Arch Dermatol. 1965;91(6):599-606.
Abstract
Patients with psoriasis receiving cytotoxic drug therapy and appropriate control subjects were exposed to (1) sensitizing doses of delayed allergens, dinitrochlorobenzene (DNCB), and paranitrosodimethylaniline (NDMA); (2) evocative patches of pentadecylcatechol (PDC); and (3) immunizing doses of a plague vaccine. Psoriatic patients so treated were very difficult to sensitize to DNCB and NDMA, reacted normally to PDC, and generally failed to give a primary or a secondary immune response to plague antigen.
Author Affiliations
SAN FRANCISCO
From the Division of Dermatology, Department of Medicine, University of California School of Medicine. Associate Professor of Dermatology (Dr. Epstein), Assistant Professor of Dermatology (Dr. Maibach).
Footnotes
Accepted for publication Dec 29, 1964.
Read before the 84th Annual Meeting of the American Dermatological Association, Kaanapali, Hawaii, June 29-30, July 1-2, 1964.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Increased Helper-Suppressor T-cell Ratio in Psoriasis
Ligresti et al.
Arch Dermatol 1982;118:966-970.
ABSTRACT
Is Methotrexate Therapy for Psoriasis Carcinogenic? A Modified Retrospective-Prospective Analysis
Bailin et al.
JAMA 1975;232:359-362.
ABSTRACT
Topical Therapy of Psoriasis With Mechlorethamine
Zackheim et al.
Arch Dermatol 1972;105:702-706.
ABSTRACT
Malignancy During Methotrexate and Steroid Therapy for Psoriasis
Harris
Arch Dermatol 1971;103:501-504.
ABSTRACT
PSORIASIS
Omura
Arch Dermatol 1970;102:694-694.
ABSTRACT
Multiple Keratoacanthomata: Response of a Case to Systemic Chemotherapy
TARNOWSKI
Arch Dermatol 1966;94:74-80.
ABSTRACT
|
